DiaMedica Therapeutics (DMAC) Reiterated Overweight by Cantor Fitzgerald: DM199 Promising
Tweet Send to a Friend
Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $25.00 price target on DiaMedica Therapeutics Inc. (NASDAQ: DMAC).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
